Invasive fungal infection · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement of clinical status: all initial symptoms resolved (asymptomatic) at day 14 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in improvement of clinical status: all initial symptoms resolved… (low certainty).
1 finding from 1 review
Intervention not reported
Improvement of clinical status: time to symptom resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
QoL (physical component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 16.2, low QoL, to 67.2, maximum QoL · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in qoL (physical component) at up to 28 days, measured on the PROMIS… (high certainty).
1 finding from 1 review
Intervention not reported
QoL (mental component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 21.2, low QoL, to 67.6, maximum QoL · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in qoL (mental component) at up to 28 days, measured on the PROMIS… (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in serious adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at day 7 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in viral clearance at day 7 (low certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: participants with new need for invasive mechanical ventilation or death at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes worsening of clinical status: participants with new need for… (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement of clinical status: participants discharged alive at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in improvement of clinical status: participants discharged alive at day… (low certainty).
1 finding from 1 review
Intervention not reported
QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes serious adverse events during the trial period (very low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at day 7 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in viral clearance at day 7 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in all‐cause mortality at day 28 (moderate certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in worsening of clinical status: admission to hospital or death within… (low certainty).
1 finding from 1 review
OutcomesTime frame of absolute effects · hospitalised people with confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review